Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab + DA-EPOCH-R for High Risk Burkitt Lymphoma (BEDROCK)
NCT07662928Phase 2Not yet recruiting
- Sponsor
- AIDS Malignancy Consortium
- Start
- Sep 2026
- Primary completion
- May 2031
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in Burkitt lymphoma (BL), sponsored by AIDS Malignancy Consortium. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
epcoritamab
03
Conditions
Burkitt lymphoma (BL)
Beyond the preview
Go deeper on NCT07662928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662928.